Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
Dexcom G7 has received FDA clearance for all diabetes types in individuals aged two and older. This next-generation continuous glucose monitoring (CGM) system boasts an overall MARD of 8.2%, making it the most accurate FDA-cleared CGM. With a 60% smaller, all-in-one wearable design, it offers a 30-minute sensor warmup and a suite of features including real-time connectivity with wearables and an upgraded mobile app. Furthermore, Dexcom's G7 is the number one covered CGM, with many users incurring low out-of-pocket costs.
- Dexcom G7 cleared for all diabetes types aged 2+.
- Overall MARD of 8.2% makes it the most accurate CGM cleared by the FDA.
- 60% smaller and all-in-one design enhances user experience.
- 30-minute sensor warmup, the fastest among CGMs.
- Improved alert settings support user management.
- Number one covered CGM with low out-of-pocket costs for many users.
- None.
-
Dexcom G7 is now cleared in the
U.S. for people with all Types of diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution -
With an overall MARD of
8.2% , Dexcom G7 is the most accurate CGM cleared by the FDA,1 building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range2,3 - Cleared as an integrated continuous glucose monitoring (iCGM) system, Dexcom G7 will be part of the most connected CGM ecosystem in the world,1 with real-time connectivity that can drive integrated insulin delivery systems, connect with wearables like the Apple Watch and integrate with popular digital health apps*
-
As the number one covered CGM on the market,4 most
Dexcom users pay less than those using other CGM systems1
Dexcom G7 now offers a more powerful and easier to use system with a small, all-in-one wearable with no fingersticks or scanning required. (Photo: Business Wire)
“There’s a reason
New features with Dexcom G7:
|
Dexcom G6 features included with Dexcom G7:
|
Proven performance with easy-to-use, customizable features
With Dexcom G7, the most recommended CGM brand among patients6 and healthcare providers7 now offers a more powerful and easier to use system with a small, all-in-one wearable, completely redesigned mobile app and no fingersticks or scanning required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels and help users spend more time in range.**,2 The system features a predictive low alert that provides a 20-minute advance warning of potentially dangerous low glucose levels so users can act quickly to avoid a hypoglycemic event. This critical feature continues to be at the forefront of the
“The first thing that stood out to me when I started using the Dexcom CGM was how easy it was to use,” said
With the most coverage,4 more users pay less for the #1 preferred CGM6,7
As diabetes becomes increasingly prevalent, it’s more important than ever for all people with diabetes to have access to the best care and technology.
-
Dexcom is the number one covered and most reimbursed CGM on the market4 with a third of patients with commercial coverage paying out-of-pocket and the majority paying less than$0 per month††,8$40 -
Dexcom has three times more patients paying than competing CGM systems8 and is currently reimbursed by more than$0 97% of private insurance1 as well as Medicare nationwide and Medicaid in 45 states -
The recent proposed rule change from the
Centers for Medicare and Medicaid Services to expand access to CGM for more people with diabetes, including those not on insulin therapy, has the potential to give millions more people in the US access to Dexcom CGM so they can more effectively manage their diabetes
“Dexcom G7 is so simple and easy to use that it should be prescribed to every person with Type 1 and Type 2 diabetes,” said
Visit Dexcom.com and get started with Dexcom G6 today to experience the benefits of CGM now. To learn more about Dexcom G7 and for additional information about when it will be available in the US, visit Dexcom.com/G7.
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including statements with respect to timing of the commercial launch of G7 in
* Compatible smart devices sold separately. To view a list of compatible smart devices, visit dexcom.com/compatibility.
† Compared to a prior generation Dexcom CGM System.
‡ Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
§ Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/registration.
|| An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity.
If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
# Separate Dexcom Follow app and internet connection required. Internet connectivity required for data sharing. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions.
** Results obtained with a prior generation Dexcom CGM System.
†† Refers to estimated out-of-pocket cost for eligible commercially insured patients from the Dexcom CGM sensor when claims are adjudicated as a pharmacy benefit, and includes benefits and offerings through available
1
2 Beck RW, et al. JAMA. 2017;317(4):371-378.
3 Welsh JB, et al. J Diabetes Sci Technol. 2022:19322968221099879.
4
5 Dexcom G7 User Guide.
6 dQ&A US Q1 2021 Diabetes Connections Patient Panel Report. 2021;69-72.
7
8 IQVIA,
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005302/en/
Media Contact
619-884-2118
james.mcintosh@dexcom.com
Investor Contact
858-203-6657
sean.christensen@dexcom.com
Source:
FAQ
What is the FDA clearance status of Dexcom G7?
What is the accuracy of the Dexcom G7 continuous glucose monitoring system?
How does Dexcom G7 integrate with other devices?
What are the financial benefits of using Dexcom G7?